Related references
Note: Only part of the references are listed.A modular master regulator landscape controls cancer transcriptional identity
Evan O. Paull et al.
CELL (2021)
Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair
Jithma P. Abeykoon et al.
BLOOD (2021)
Therapeutic Targeting of Exportin-1 in Childhood Cancer
Basia Galinski et al.
CANCERS (2021)
Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses
Daniel J. Landsburg et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Wilms Tumor (Nephroblastoma), Version 2.2021
Frank Balis et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Phase 1 trial of selinexor in children and adolescents with recurrent/refractory solid and CNS tumors (ADVL1414): A Children's Oncology Group Phase 1 Consortium trial
Adam L. Green et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages
Aleksandar Obradovic et al.
CELL (2021)
Activity of Vincristine and Irinotecan in Diffuse Anaplastic Wilms Tumor and Therapy Outcomes of Stage II to IV Disease: Results of the Children's Oncology Group AREN0321 Study
Najat C. Daw et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Preclinical evaluation of XPO1 inhibition in Wilms tumors.
Michael Vincent Ortiz et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
XPO1-dependent nuclear export as a target for cancer therapy
Nancy G. Azizian et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma
Joel G. Turner et al.
CANCER RESEARCH (2020)
p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors
Alessandro Carugo et al.
CANCER CELL (2019)
The genomic landscape of pediatric cancers: Implications for diagnosis and treatment
E. Alejandro Sweet-Cordero et al.
SCIENCE (2019)
Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report
David B. Dix et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma
Ajai Chari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Identification and Analyses of Extra-Cranial and Cranial Rhabdoid Tumor Molecular Subgroups Reveal Tumors with Cytotoxic T Cell Infiltration
Hye-Jung E. Chun et al.
CELL REPORTS (2019)
High-dose treatment for malignant rhabdoid tumor of the kidney: No evidence for improved survivalThe Gesellschaft fur Padiatrische Onkologie und Hamatologie (GPOH) experience
Rhoikos Furtwaengler et al.
PEDIATRIC BLOOD & CANCER (2018)
Precision medicine in pediatric oncology
Suzanne J. Forrest et al.
CURRENT OPINION IN PEDIATRICS (2018)
The landscape of genomic alterations across childhood cancers
Susanne N. Groebner et al.
NATURE (2018)
A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors
Mariano J. Alvarez et al.
NATURE GENETICS (2018)
Quantitative assessment of protein activity in orphan tissues and single cells using the metaVIPER algorithm
Hongxu Ding et al.
NATURE COMMUNICATIONS (2018)
Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma
Presha Rajbhandari et al.
CANCER DISCOVERY (2018)
Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents
Trinayan Kashyap et al.
Oncotarget (2018)
Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial.
Komal L. Jhaveri et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer
Tyler Risom et al.
NATURE COMMUNICATIONS (2018)
Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor
Vinod Vijay Subhash et al.
SCIENTIFIC REPORTS (2018)
Association between NER Pathway Gene Polymorphisms and Wilms Tumor Risk
Jinhong Zhu et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2018)
hase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia
Andrew E. Place et al.
BLOOD (2018)
KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells
J. Etchin et al.
LEUKEMIA (2017)
Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma
Manoj Garg et al.
ONCOTARGET (2017)
A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor
Samantha Gadd et al.
NATURE GENETICS (2017)
Outcome of patients with intracranial relapse enrolled on national Wilms Tumor Study Group clinical trials
Rajkumar Venkatramani et al.
PEDIATRIC BLOOD & CANCER (2017)
An Integrated Systems Biology Approach Identifies TRIM25 as a Key Determinant of Breast Cancer Metastasis
Logan A. Walsh et al.
CELL REPORTS (2017)
Systematic, network-based characterization of therapeutic target inhibitors
Yao Shen et al.
PLOS COMPUTATIONAL BIOLOGY (2017)
Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin
Manoj Garg et al.
SCIENTIFIC REPORTS (2017)
TP53 alterations in Wilms tumour represent progression events with strong intratumour heterogeneity that are closely linked but not limited to anaplasia
Jenny Wegert et al.
JOURNAL OF PATHOLOGY CLINICAL RESEARCH (2017)
Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma
John Kuruvilla et al.
BLOOD (2017)
A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia
Ramiro Garzon et al.
BLOOD (2017)
The recurrent architecture of tumour initiation, progression and drug sensitivity
Andrea Califano et al.
NATURE REVIEWS CANCER (2017)
Genome-Wide Profiles of Extra-cranial Malignant Rhabdoid Tumors Reveal Heterogeneity and Dysregulated Developmental Pathways
Hye-Jung E. Chun et al.
CANCER CELL (2016)
Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group
Ariadne H. A. G. Ooms et al.
CLINICAL CANCER RESEARCH (2016)
XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus
Parvathi Ranganathan et al.
CLINICAL CANCER RESEARCH (2016)
Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia
Thomas B. Alexander et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study
Tasnim Chagtai et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group
Eric J. Gratias et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma
Mrinal M. Gounder et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Functional characterization of somatic mutations in cancer using network-based inference of protein activity
Mariano J. Alvarez et al.
NATURE GENETICS (2016)
Integrated genetic and pharmacologic interrogation of rare cancers
Andrew L. Hong et al.
NATURE COMMUNICATIONS (2016)
XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IkBa and overcomes acquired proteasome inhibitor resistance in human multiple myeloma
Joel G. Turner et al.
ONCOTARGET (2016)
Implementation of next generation sequencing into pediatric hematologyoncology practice: moving beyond actionable alterations
Jennifer A. Oberg et al.
GENOME MEDICINE (2016)
Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors The Individualized Cancer Therapy (iCat) Study
Marian H. Harris et al.
JAMA ONCOLOGY (2016)
Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth
Rajen J. Mody et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology
Donavan T. Cheng et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2015)
Age-related somatic mutations in the cancer genome
Brandon Milholland et al.
ONCOTARGET (2015)
Predicting Drug Response in Human Prostate Cancer from Preclinical Analysis of In Vivo Mouse Models
Antonina Mitrofanova et al.
CELL REPORTS (2015)
KPT-330 has antitumour activity against non-small cell lung cancer
H. Sun et al.
BRITISH JOURNAL OF CANCER (2014)
CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications
Y-T Tai et al.
LEUKEMIA (2014)
A community computational challenge to predict the activity of pairs of compounds
Mukesh Bansal et al.
NATURE BIOTECHNOLOGY (2014)
TP53 Mutational Status Is a Potential Marker for Risk Stratification in Wilms Tumour with Diffuse Anaplasia
Mariana Maschietto et al.
PLOS ONE (2014)
Comprehensive Genomic Analysis of Rhabdomyosarcoma Reveals a Landscape of Alterations Affecting a Common Genetic Axis in Fusion-Positive and Fusion-Negative Tumors
Jack F. Shern et al.
CANCER DISCOVERY (2014)
Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth
Kimberly H. Kim et al.
CANCER GENETICS (2014)
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Michael I. Love et al.
GENOME BIOLOGY (2014)
STAR: ultrafast universal RNA-seq aligner
Alexander Dobin et al.
BIOINFORMATICS (2013)
Direct Reversal of Glucocorticoid Resistance by AKT Inhibition in Acute Lymphoblastic Leukemia
Erich Piovan et al.
CANCER CELL (2013)
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Michael S. Lawrence et al.
NATURE (2013)
Children's Oncology Group's 2013 blueprint for research: Renal tumors
Jeffrey S. Dome et al.
PEDIATRIC BLOOD & CANCER (2013)
Nuclear export of proteins and drug resistance in cancer
Joel G. Turner et al.
BIOCHEMICAL PHARMACOLOGY (2012)
Importin 7 and Exportin 1 Link c-Myc and p53 to Regulation of Ribosomal Biogenesis
Lior Golomb et al.
MOLECULAR CELL (2012)
The transcriptional network for mesenchymal transformation of brain tumours
Maria Stella Carro et al.
NATURE (2010)
The role of SMARCB1/INI1 in development of rhabdoid tumor
Charles W. M. Roberts et al.
CANCER BIOLOGY & THERAPY (2009)
Rapid detection of mycoplasma in continuous cell lines using a selective biochemical test
E. Mariotti et al.
LEUKEMIA RESEARCH (2008)
Treatment of anaplastic histology Wilms' tumor: Results from the fifth National Wilms' Tumor Study
Jeffrey S. Dome et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
ARACNE: An algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context
AA Margolin et al.
BMC BIOINFORMATICS (2006)
Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: A report from the National Wilms Tumor Study Group
PE Grundy et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
PAGE: Parametric analysis of gene set enrichment
SY Kim et al.
BMC BIOINFORMATICS (2005)
Establishment of a cell line from a malignant rhabdoid tumor of the liver lacking the function of two tumor suppressor genes, hSNF5/INI1 and p16
H Kuroda et al.
CANCER GENETICS AND CYTOGENETICS (2005)
The SWI/SNF complex - Chromatin and cancer
CWM Roberts et al.
NATURE REVIEWS CANCER (2004)
Translocation (1;22)(p36;q11.2) with concurrent del(22)(q11.2) resulted in homozygous deletion of SNF5/INI1 in a newly established cell line derived from extrarenal rhabdoid tumor
A Misawa et al.
JOURNAL OF HUMAN GENETICS (2004)
Share Paper
